Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy

Annalisa Petrelli; Rosachiara Carollo; Marilisa Cargnelutti; Flora Iovino; Maurizio Callari; Daniela Cimino; Matilde Todaro; Laura Rosa Mangiapane; Alessandro Giammona; Adriana Cordova; Filippo Montemurro; Daniela Taverna; Maria Grazia Daidone; Giorgio Stassi; Silvia Giordano

doi:10.18632/oncotarget.27151

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy

PDF | How to cite

Oncotarget. 2019; 10:5003-5004. https://doi.org/10.18632/oncotarget.27151

Metrics: PDF 1442 views | ?

Annalisa Petrelli^1,*, Rosachiara Carollo^2,*, Marilisa Cargnelutti¹, Flora Iovino², Maurizio Callari³, Daniela Cimino⁴, Matilde Todaro², Laura Rosa Mangiapane², Alessandro Giammona², Adriana Cordova², Filippo Montemurro¹, Daniela Taverna⁴, Maria Grazia Daidone³, Giorgio Stassi^2,* and Silvia Giordano^1,*

¹ University of Torino School of Medicine, Candiolo Cancer Institute-FPO, IRCCS, Str. Provinciale, Candiolo, Torino, Italy
² Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo,Palermo, Italy
³ Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
⁴ Molecular Biotechnology Center (MBC), Department of Oncological Sciences, Center for Molecular Systems Biology, Via Nizza, University of Torino, Torino, Italy

Published: August 13, 2019

This article has been corrected: Due to errors in image assembly, the flow cytometry profiles depicting the isotype matched control (IMC) for CD49f on both scramble (scr) and miR-100 reported in Figure 6 are incorrect. Additionally, we noticed that the IMC reported for CD24 and CD10 in miR-100 are the same. Being both CD24 allophycocianin (APC) and CD10 APC IgG1, they should have the same IMC, as already reported. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:2315–2330. DOI: https://doi.org/10.18632/oncotarget.2962.

Figure 6: Ectopic expression of miR-100 reduces stem cell markers and induces markers of differentiation. Flow cytometry analysis of CD44, CD24, CD10, CD49f and EpCAM expression in BrCSCs (P5) scramble and stably expressing miR-100. IMC: Isotype Matched Control.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27151

Publication Alerts

Corrections:

Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy